Delayed Function of Renal Transplant
6
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients
The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population